TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-AMC as substrate preincubated with enzyme for 1 hr followed by substrate addition and measured for 1 hr...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-morpholine as substrate preincubated for 30 mins followed by substrate addition by fluorescence bas...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-Morpholine as substrate preincubated with enzyme for 1 hr followed by substrate addition and measur...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Inhibition of FLAG-tagged UCHL1 (unknown origin) expressed in CAL-51 cells using HA-Ub-VME as substrate incubated for 30 mins by HTRF assayMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics
US Patent
Mission Therapeutics
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair